Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MVA-BN · Jynneos

Vaccine · Immune activation · developed by Bavarian Nordic

Approved FDA, Sep 2019
2 Registered trials

What is MVA-BN?

MVA-BN is a live, attenuated, non-replicating modified vaccinia Ankara vaccine that induces cellular and humoral immune responses. It is studied for the prevention of smallpox and mpox (monkeypox).

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Jynneos
Drug type
Vaccine
Mechanism
Immune activation
Pathways
cellular and humoral immune responses
Therapy area
Infectious disease
Developer
Bavarian Nordic A/S
In trials of
ICLR, SIGA
FDA status
Approved as Jynneos (September 24, 2019), BLA125678
UNII
TU8J357395

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07199569 Phase 2 Monkeypox (Mpox) Active not recruiting ICLR
NCT04957485 Phase 2 Smallpox Active not recruiting SIGA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Monkeypox (Mpox)Smallpox

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.